Ubiquitous Learning Project Using Life-logging Technology in Japan von Ogata, Hiroaki, Hou, Bin, Li, Mengmeng, Uosaki, Noriko, Mouri, Kosuke, Liu, Songran

Volltext

Tumor metabolic volume by 18F-FDG-PET as a prognostic predictor of first-line pembrolizumab for NSCLC patients with PD-L1 ≥ 50 von Yamaguchi, Ou, Kaira, Kyoichi, Hashimoto, Kosuke, Mouri, Atsuto, Shiono, Ayako, Miura, Yu, Murayama, Yoshitake, Kobayashi, Kunihiko, Kagamu, Hiroshi, Kuji, Ichiei

Volltext

Prospective assessment using 18F-FDG PET/CT as a novel predictor for early response to PD-1 blockade in non-small-cell lung cancer von Yamaguchi, Ou, Kaira, Kyoichi, Naruse, Ichiro, Umeda, Yukihiro, Honda, Takeshi, Watanabe, Satoshi, Ichikawa, Kosuke, Tateishi, Kazunari, Kasahara, Norimitsu, Higuchi, Tetsuya, Hashimoto, Kosuke, Shinomiya, Shun, Miura, Yu, Shiono, Ayako, Mouri, Atsuto, Imai, Hisao, Iizuka, Kunihiko, Ishizuka, Tamotsu, Minato, Koichi, Suda, Satoshi, Kagamu, Hiroshi, Mori, Keita, Kuji, Ichiei, Seki, Nobuhiko

Volltext

CD4 + T-cell Immunity in the Peripheral Blood Correlates with Response to Anti-PD-1 Therapy von Kagamu, Hiroshi, Kitano, Shigehisa, Yamaguchi, Ou, Yoshimura, Kenichi, Horimoto, Katsuhisa, Kitazawa, Masashi, Fukui, Kazuhiko, Shiono, Ayako, Mouri, Atsuhito, Nishihara, Fuyumi, Miura, Yu, Hashimoto, Kosuke, Murayama, Yoshitake, Kaira, Kyoichi, Kobayashi, Kunihiko

Volltext

Clinical significance of visual cardiac 18F-FDG uptake in advanced non-small cell lung cancer von Hashimoto, Kosuke, Kaira, Kyoichi, Imai, Hisao, Yamaguchi, Ou, Mouri, Atsuto, Shiono, Ayako, Miura, Yu, Kobayashi, Kunihiko, Kagamu, Hiroshi, Kuji, Ichiei

Volltext

Improved efficacy of ramucirumab plus docetaxel after nivolumab failure in previously treated non‐small cell lung cancer patients von Shiono, Ayako, Kaira, Kyoichi, Mouri, Atsuto, Yamaguchi, Ou, Hashimoto, Kosuke, Uchida, Takahiro, Miura, Yu, Nishihara, Fuyumi, Murayama, Yoshitake, Kobayashi, Kunihiko, Kagamu, Hiroshi

Volltext

Establishing a whole blood CD4 + T cell immunity measurement to predict response to anti-PD-1 von Yamaguchi, Ou, Atarashi, Kazuyuki, Yoshimura, Kenichi, Shiono, Ayako, Mouri, Atsuhito, Nishihara, Fuyumi, Miura, Yu, Hashimoto, Kosuke, Miyamoto, Yoshiaki, Uga, Hitoshi, Seki, Nobuo, Matsushima, Tomoko, Kikukawa, Norihiro, Kobayashi, Kunihiko, Kaira, Kyoichi, Kagamu, Hiroshi

Volltext

Clinical difference between discontinuation and retreatment with nivolumab after immune-related adverse events in patients with lung cancer von Mouri, Atsuto, Kaira, Kyoichi, Yamaguchi, Ou, Shiono, Ayako, Miura, Yu, Hashimoto, Kosuke, Nishihara, Fuyumi, Murayama, Yoshitake, Kobayashi, Kunihiko, Kagamu, Hiroshi

Volltext

Comparative analysis of different response criteria at early phase after PD-1 blockade in non-small lung cancer von Kaira, Kyoichi, Yamaguchi, Ou, Naruse, Ichiro, Umeda, Yukihiro, Honda, Takeshi, Watanabe, Satoshi, Ichikawa, Kosuke, Yanagisawa, Shin, Kasahara, Norimitsu, Higuchi, Tetsuya, Hashimoto, Kosuke, Miura, Yu, Shiono, Ayako, Mouri, Atsuto, Imai, Hisao, Iizuka, Kunihiko, Ishizuka, Tamotsu, Minato, Koichi, Suda, Satoshi, Kagamu, Hiroshi, Mori, Keita, Seki, Nobuhiko, Kuji, Ichiei

Volltext

Single-Cell Analysis Reveals a CD4+ T-cell Cluster That Correlates with PD-1 Blockade Efficacy von Kagamu, Hiroshi, Yamasaki, Satoshi, Kitano, Shigehisa, Yamaguchi, Ou, Mouri, Atsuto, Shiono, Ayako, Nishihara, Fuyumi, Miura, Yu, Hashimoto, Kosuke, Imai, Hisao, Kaira, Kyoichi, Kobayashi, Kunihiko, Kanai, Yae, Shibata, Tatsuhiro, Horimoto, Katsuhisa

Volltext

Radiotherapy is an independent prognostic marker of favorable prognosis in non‐small cell lung cancer patients after treatment with the immune checkpoint inhibitor, nivolumab von Yamaguchi, Ou, Kaira, Kyoichi, Hashimoto, Kosuke, Mouri, Atsuto, Miura, Yu, Shiono, Ayako, Nishihara, Fuyumi, Murayama, Yoshitake, Noda, Shin‐ei, Kato, Shingo, Kobayashi, Kunihiko, Kagamu, Hiroshi

Volltext

A retrospective evaluation of therapeutic efficacy and safety of chemoradiotherapy in older patients (aged ≥ 75 years) with limited-disease small cell lung cancer: insights from tw... von Shiono, Ayako, Imai, Hisao, Endo, Satoshi, Katayama, Kazuki, Sato, Hideaki, Hashimoto, Kosuke, Miura, Yu, Okazaki, Shohei, Abe, Takanori, Mouri, Atsuto, Kaira, Kyoichi, Masubuchi, Ken, Kobayashi, Kunihiko, Minato, Koichi, Kato, Shingo, Kagamu, Hiroshi

Volltext

Chemoradiotherapy followed by durvalumab in patients with unresectable advanced non‐small cell lung cancer: Management of adverse events von Miura, Yu, Mouri, Atsuto, Kaira, Kyoichi, Yamaguchi, Ou, Shiono, Ayako, Hashimoto, Kosuke, Nishihara, Fuyumi, Shinomiya, Shun, Akagami, Tomoe, Murayama, Yoshitake, Abe, Takanori, Noda, Shin‐ei, Kato, Shingo, Kobayashi, Kunihiko, Kagamu, Hiroshi

Volltext

Impact of Cachexia and First‐Line Systemic Therapy for Previously Untreated Advanced Non‐Small Cell Lung Cancer: NEJ050A von Miura, Keita, Shukuya, Takehito, Furuya, Naoki, Morita, Ryo, Kisohara, Akira, Mouri, Atsuto, Watanabe, Satoshi, Tanaka, Hisashi, Hirata, Aya, Hakozaki, Taiki, Hamai, Kosuke, Matsumoto, Naoko, Watanabe, Kana, Ashinuma, Hironori, Miyauchi, Eisaku, Sugano, Koji, Hosokawa, Shinobu, Amano, Koji, Morita, Satoshi, Kobayashi, Kunihiko, Maemonodo, Makoto, Takahashi, Kazuhisa

Volltext

Correction to: Re-challenge of afatinib after 1st generation EGFR-TKI failure in patients with previously treated non-small cell lung cancer harboring EGFR mutation von Yamaguchi, Ou, Kaira, Kyoichi, Mouri, Atsuto, Shiono, Ayako, Hashimoto, Kosuke, Miura, Yu, Nishihara, Fuyumi, Murayama, Yoshitake, Kobayashi, Kunihiko, Kagamu, Hiroshi

Volltext

Effectiveness of EGFR‐TKI rechallenge immediately after PD‐1 blockade failure von Kaira, Kyoichi, Kobayashi, Kunihiko, Shiono, Ayako, Yamaguchi, Ou, Hashimoto, Kosuke, Mouri, Atsuto, Shinomiya, Shun, Miura, Yu, Imai, Hisao, Kagamu, Hiroshi

Volltext

Efficacy and Feasibility of Programmed Death-1/Programmed Death Ligand-1 Blockade Therapy in Non-Small Cell Lung Cancer Patients With High Antinuclear Antibody Titers von Mouri, Atsuto, Kaira, Kyoichi, Yamaguchi, Ou, Hashimoto, Kosuke, Miura, Yu, Shiono, Ayako, Shinomiya, Shun, Akagami, Tomoe, Imai, Hisao, Kobayashi, Kunihiko, Kagamu, Hiroshi

Volltext

Potential of FDG-PET as Prognostic Significance after anti-PD-1 Antibody against Patients with Previously Treated Non-Small Cell Lung Cancer von Hashimoto, Kosuke, Kaira, Kyoichi, Yamaguchi, Ou, Mouri, Atsuto, Shiono, Ayako, Miura, Yu, Murayama, Yoshitake, Kobayashi, Kunihiko, Kagamu, Hiroshi, Kuji, Ichiei

Volltext

Clinical significance of antinuclear antibody as prognostic marker for first-line pembrolizumab in advanced non-small cell lung cancer von Mouri, Atsuto, Kaira, Kyoichi, Yamaguchi, Ou, Hashimoto, Kosuke, Miura, Yu, Shiono, Ayako, Kawasaki, Tomonori, Kobayashi, Kunihiko, Imai, Hisao, Kagamu, Hiroshi

Volltext

Pre‐existing interstitial lung disease does not affect prognosis in non‐small cell lung cancer patients with PD‐L1 expression ≥50% on first‐line pembrolizumab von Yamaguchi, Ou, Kaira, Kyoichi, Shinomiya, Shun, Mouri, Atsuto, Hashimoto, Kosuke, Shiono, Ayako, Miura, Yu, Akagami, Tomoe, Imai, Hisao, Kobayashi, Kunihiko, Kagamu, Hiroshi

Volltext